Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 446-449

  Badley, Andrew D ^b   Patel, Robin ^b   Portela, Daniel F ^b   Harmsen, William S ^b   Smith, Thomas F ^b   Ilstrup, Duane M ^b   Steers, Jeffery L ^b   Wiesner, Russell H ^b   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK FACTOR; VIREMIA;

EID: 0030054164     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.446     Document Type: Article

References (14)

1. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Medical Book, 1994:647-59.
2. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1993;119:984-91.
3. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994;58:779-85.
4. Stratta RJ, Shaefer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992;127:55-64.
5. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123:18-26.
6. van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991;164:265-70.
7. Patel R, Smith TF, Espy M, et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis 1995;171:1010-4.
8. Pillay D, Ali AA, Liu SF, Kops E, Sweny P, Griffiths PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 1993;56:103-8.
9. Meyers JD, Ljungman P, Fischer LD. Cytomegalovirus excretion as a predictor of disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990;162:373-80.
10. Zurlo JJ, O'Neill D, Polis MA, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med 1993;118:12-7.
11. Paya CV, Hermans PE, Wiesner RH, Smith TF, Ilstrup D, Krom RAF. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993;18:185-95.
12. Paya CV, Smith TF, Ludwig J, Hermans PE. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 1989;64:670-5.
13. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994;120:375-81, comment in 1994;121:385.
14. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for CMV disease in liver transplantation. J Infect Dis 1995;171:1014-8.